University of Virginia
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1819-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.virginia.edu
Clinical Trials
639
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (512 trials with phase data)• Click on a phase to view related trials
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
- Conditions
- Huntington DiseaseParkinson Disease
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 136
- Registration Number
- NCT07213648
- Locations
- 🇺🇸
Univeristy of Virginia School of Nursing, Charlottesville, Virginia, United States
Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes
- Conditions
- Type 1 Diabetes (T1D)Glycemic Control for Diabetes MellitusInsulinKetonesCardiovascular Health
- Interventions
- Drug: CIR-0602KDrug: Placebo
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 40
- Registration Number
- NCT07186660
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
A Study of a Test for Postpartum Depression at Home
- Conditions
- Postpartum Depression (PPD)Pregnancy
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 1000
- Registration Number
- NCT07186309
Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA)
- Conditions
- MINOCAShortness of BreathAtherosclerotic Heart Disease of Native Coronary Artery
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 25
- Registration Number
- NCT07182955
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
- Conditions
- Heart Failure Preserved Ejection FractionEpicardial Adipose Tissue
- Interventions
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 192
- Registration Number
- NCT07178145
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 128
- Next
News
Virginia Approves Incentive Packages for AstraZeneca and Eli Lilly Manufacturing Plants
Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County.
UVA Launches First-of-Its-Kind Psilocybin Trial for Prolonged Grief Disorder
The University of Virginia has initiated a groundbreaking clinical trial testing a single 25-milligram dose of psilocybin to treat prolonged grief disorder, a clinically recognized condition affecting approximately 10% of mourning individuals.
University of Virginia Expands Manning Institute of Biotechnology with $66M Additional Contract
Skanska has secured an additional $66 million contract with the University of Virginia to construct the Paul and Diane Manning Institute of Biotechnology, bringing advanced translational research capabilities to the Commonwealth.
Ascidian Therapeutics Advances RNA Exon Editing Platform with Key Leadership Appointments and Clinical Progress
Ascidian Therapeutics has assembled a distinguished Scientific Advisory Board featuring globally recognized RNA biology experts to guide its RNA exon editing platform development.
UVA Launches $30M Trial to Test Ketamine for Life-Threatening Seizures
The University of Virginia has secured a $9.3 million NIH grant as initial funding for a $30 million clinical trial investigating ketamine's potential in treating status epilepticus, a life-threatening seizure condition.
UVA Initiates Clinical Trial of AI-Enhanced Automated Insulin Delivery System for Type 1 Diabetes
• The University of Virginia is launching a clinical trial to evaluate an AI-powered "Bolus Priming System with Reinforcement Learning" (BPS_RL) for automated insulin delivery in Type 1 diabetes patients. • The three-week trial will involve 16 adult participants testing the enhanced system, which integrates with existing AIDANET technology including a phone app, Dexcom glucose monitor, and Tandem insulin pump. • The innovative system aims to improve blood sugar control during meals and overnight without requiring user input, potentially reducing the burden of diabetes management.
Cannabinoids Show Promise in Managing Peripheral Neuropathy Symptoms
A systematic review of 14 clinical trials indicates that cannabis-based medicines may effectively treat peripheral neuropathy by reducing neuropathic pain.
Daratumumab/Lenalidomide Combo Improves MRD Negativity in Myeloma Maintenance
A post hoc analysis of the AURIGA trial reveals that adding daratumumab to lenalidomide enhances minimal residual disease (MRD)-negativity conversion rates in multiple myeloma patients post-transplant.